$230 Million is the total value of Aisling Capital Management LP's 14 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 7.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BBIO | Buy | BridgeBio (BBIO) | $115,693,000 | -13.9% | 3,989,412 | +4.0% | 50.40% | -2.2% |
| EIDX | Eidos Therapeutics, Inc. (EIDIX) | $55,047,000 | -14.6% | 1,123,630 | 0.0% | 23.98% | -2.9% | |
| AVRO | Buy | AVROBIO, Inc. (AVRO) | $15,712,000 | -12.6% | 1,009,779 | +13.1% | 6.84% | -0.6% |
| SNDX | New | Syndax Pharmaceuticals Inc. (SNDX) | $9,599,000 | – | 875,000 | +100.0% | 4.18% | – |
| BCEL | Atreca (BCEL) | $6,416,000 | +7.0% | 387,653 | 0.0% | 2.80% | +21.6% | |
| AGLE | Aeglea Biotherapeutics Inc (AGLE) | $6,017,000 | -39.0% | 1,291,151 | 0.0% | 2.62% | -30.6% | |
| RCUS | Arcus Biosciences, Inc. (RCUS) | $4,627,000 | +37.4% | 333,333 | 0.0% | 2.02% | +56.3% | |
| SNSS | Sunesis Pharmaceuticals, Inc. (SNSS) | $4,190,000 | +22.8% | 10,100,000 | 0.0% | 1.82% | +39.6% | |
| MRKR | Marker Therapeutics, Inc. (MRKR) | $3,800,000 | -34.0% | 2,000,000 | 0.0% | 1.66% | -25.0% | |
| OBSV | ObsEva SA (OBSV) | $3,341,000 | -36.9% | 1,386,338 | 0.0% | 1.46% | -28.3% | |
| VRNA | Verona Pharma plc (VRNA) | $1,828,000 | -28.3% | 443,596 | 0.0% | 0.80% | -18.5% | |
| ZSAN | Zosano Pharma Corporation (ZSAN) | $1,528,000 | -63.0% | 2,718,226 | 0.0% | 0.67% | -57.9% | |
| Nabriva Therapeutics plc (NBRV) | $1,098,000 | -56.5% | 1,910,287 | 0.0% | 0.48% | -50.5% | ||
| ACRS | Aclaris Theraputics Inc (ACRS) | $660,000 | -45.0% | 634,455 | 0.0% | 0.29% | -37.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Verona Pharma plc (VRNA) | 20 | Q3 2023 | 23.0% |
| AVROBIO, Inc. (AVRO) | 20 | Q3 2023 | 13.6% |
| Aclaris Theraputics Inc. (ACRS) | 20 | Q3 2023 | 6.6% |
| Aeglea Biotherapeutics Inc. (AGLE) | 19 | Q2 2023 | 7.5% |
| BridgeBio Pharma Inc. (BBIO) | 18 | Q3 2023 | 67.3% |
| Marker Therapeutics, Inc. (MRKR) | 18 | Q1 2023 | 11.7% |
| Atreca Inc. (BCEL) | 18 | Q3 2023 | 3.1% |
| Syndax Pharmaceuticals, Inc. (SNDX) | 15 | Q3 2023 | 17.2% |
| Zosano Pharma Corporation (ZSAN) | 15 | Q2 2022 | 5.8% |
| ObsEva SA (OBSV) | 14 | Q1 2022 | 18.5% |
View Aisling Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-03 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-18 |
| 13F-HR | 2021-11-12 |
View Aisling Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.